Neuroscience is a $600+ Billion Market

- brain disorders are a major cause of disability and the second leading cause of death globally. As of now, 12 mental health disorders affect nearly 970 million people, which is about one-eighth of the global population. - despite the high prevalence of brain disorders, innovations in neuroscience have been limited, especially in the development of new psychopharmacological drugs, since the last century. - the report estimates the GNM to be worth $612 billion in 2022, with a projection to grow to $721 billion by 2026. This growth is expected to have a compound annual growth rate (CAGR) of 4.2%. - GNM is segmented into diagnostic solutions, drug therapies, and non-drug therapies. Different segments show varying growth rates, with digital health expected to grow the most rapidly, as well as molecular diagnostics. - the development of effective brain therapies is hindered by a limited understanding of the brain's biology, the inadequacy of traditional pharmacological treatments, and the lack of early diagnostic tools. - North America and Europe dominate the GNM, but the Asia-Pacific region is expected to grow significantly in high-growth segments like digital health. - medical imaging and next-generation sequencing technologies are key drivers in the neuroscience diagnostic market. - pharmacological interventions against multiple sclerosis, anxiety, mood disorders, and substance abuse disorders dominate the neuroscience drug market. - the neuropharmacology landscape faces challenges due to historically low efficiency in clinical development compared to other therapeutic areas (you all know that anyway, a "graveyard" of drug candidates). - the report suggests that investment bodies adjust strategies based on current revenue levels across GNM segments and target regions, with an emphasis on high-growth segments like digital health and molecular diagnostics.